Clinical & Translational

SeraCare is licensing UCSF's T21, T18, and T13 trophoblast cell line materials to develop NIPT reference materials.

Shuwen Biotech will develop, manufacture, and market a test for a Hengrui cancer drug, as well as screen patients with the test for upcoming clinical trials.

The NGS panel looks for mutations in KRAS, BRAF, EGFR, ROS1, and ALK and will be available through Admera's sales partner Rosetta Genomics. 

Under the terms of the pact, the partners will integrate Translational's pharmacogenetics knowledgebase and interpretation platform with Xifin's laboratory information system.

The company reported $2.22 billion in second quarter revenues, with $620.8 million attributable to the Covance acquisition.